Condition: Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Effectiveness: ★★★ Ease of Use: ★★★ Satisfactory Index: ★★★ Therapeautic drug, Ibrance (Chemical name: Palbociclib), recently approved by the U.S. Food and Drug Administration in February 2015, is intended to be paired with the hormonal therapy medicine Femara (Chemical name: Letrozole) as a comprehensive treatment for locally advanced-stage or metastatic, hormone-receptor-positive, HER2-negative […]